PSTV

Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company focused on developing and commercializing targeted radiotherapeutics for rare and difficult-to-treat cancers. Headquartered in Austin, Texas, the company specializes in complex central nervous system cancers, including recurrent glioblastoma and leptomeningeal metastases. Its lead investigational product candidate, rhenium-186 obisbemeda, is a radiotherapeutic being evaluated for direct delivery to the central nervous system for adult patients with recurrent glioblastoma and leptomeningeal metastases from various solid tumors. The company's approach combines imaging and therapeutic capabilities in a single platform, utilizing proprietary microparticle technology designed to deliver targeted radiation directly to tumor sites while minimizing damage to healthy tissue. Plus Therapeutics holds an exclusive worldwide license from the University of Texas M.D. Anderson Cancer Center for certain intellectual property related to its rhenium-based technology. The company transitioned from NanoTx Therapeutics following its 2019 reverse merger with Cypress Pharmaceutical and subsequent strategic refocus on oncology. As a publicly traded entity on the NASDAQ under ticker PSTV, Plus Therapeutics continues advancing its clinical programs through FDA-regulated trials while exploring additional applications for its radiotherapeutic platform across various cancer types affecting the central nervous system.